Biophytis - Convening of another combined General Meeting at a Later Date
Paris (France), Cambridge (Massachusetts, USA), May 11, 2020, 7:30 p.m. CEST -
BIOPHYTIS (Euronext Growth Paris: ALBPS) a clinical-stage biotechnology company
specialized in the development of drug candidates for treatment of aged related
diseases, amongst which neuromuscular diseases, informs its shareholders that
the combined General Meeting held on May 11, 2020 was unable to deliberate, as
the required quorum was not reached.
Biophytis' combined General Meeting took place today behind closed doors, due
to the COVID-19 pandemic. The shareholders taking part in the vote owned
collectively 6 649 625 shares, or 16.74 % of the share capital, and 19.92 % of
the voting rights.
The 20% quorum necessary for holding an ordinary general meeting on first call
and the 25% quorum necessary for holding an extraordinary general meeting on
first call have not been reached. Therefore, in the absence of the quorum
required to rule on the ordinary and extraordinary resolutions, none of the
proposed resolutions as listed in the meeting notice published in the Bulletin
des Annonces Légales Obligatoires n° 42 of April 6, 2020, has been put to the
vote of the shareholders and the general meeting is adjourned.
Shareholders will therefore be invited to another combined General Meeting, on
the second call, to be held at a later date with the same agenda.
All of the documents regarding this combined General Meeting are available to
shareholders on the Company's website: www.biophytis.com, in the section
Investors / General Assembly 2020:
If you are a Biophytis shareholder and wish to vote on the resolutions, you
* vote via your bank's web portal, if your bank subscribes to the VOTACCESS
platform, this method is strongly recommended in the current context of
* vote by post or proxy, in accordance with the T&Cs indicated in the
Shareholders' letter and in the Bulletin des Annonces Légales Obligatoires
n° 42 of April 6, 2020 available on Biophytis' website
The vote of shareholders who submitted their vote via the post, email or the
Internet for the first general meeting remains valid and counted for the
general meeting on the second call.
Shareholders who did not vote by post or proxy as part of the first combined
General Meeting will be invited to send their forms and shareholder
certificates after publication of the new meeting notice. By post : CACEIS
Corporate Trust, Service Assemblées Générales Centralisées - 14, rue Rouget
de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or via email:
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, especially
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of BIO101 is being
developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company
plans to start the clinical development in H2 2020.
Sarconeos (BIO101) will also be developed as a treatment for Covid-19
(Coronavirus) for which the company has filed a clinical trial application with
the French Regulatory Authority (ANSM).
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825).
For more information www.biophytis.com.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO